

FIGURE 1





FIGURE 2A

SC Salmeterol Xinafoate Pharmacokinetics




FIGURE 2B

SC Fluticasone Propionate (FP) Pharmacokinetics




FIGURE 3A





FIGURE 3B



Title: *METHODS FOR ADMINISTRATION AND FORMULATIONS FOR THE TREATMENT OF REGIONAL ADIPOSE TISSUE*

Inventor(s): DOBAK, John Daniel, et al.

Applicant: LITHERA, INC.

Application No.: Unassigned


Docket No.: 35560-705.601

Filed by EFS-Web

Sheet 4 of 7

FIGURE 4

Change in Full Waist From BL By Total Weekly Dose of SX



Note: Total weekly dose SX defined by dose and frequency of injection;
1.0 µg FP injected with each dose of SX

FIGURE 5A

SC Salmeterol Xinafoate (SX) Pharmacokinetics






FIGURE 5B

SC Fluticasone Propionate (FP) Pharmacokinetics

FIGURE 6
Full Waist - All Subjects

*p<0.05

**p<0.01

FIGURE 7A





FIGURE 7B



Title: *METHODS FOR ADMINISTRATION AND FORMULATIONS FOR THE TREATMENT OF REGIONAL ADIPOSE TISSUE*

Inventor(s): DOBAK, John Daniel, et al.

Applicant: LITHERA, INC.

Application No.: Unassigned

Docket No.: 35560-705.601

Filed by EFS-Web

Sheet 7 of 7

FIGURE 8

